DYNAVAX TECHNOLOGIES CORPORATION Item 8.01. Other Events
On
In the trial, four doses of HEPLISAV-B induced a seroprotection rate of 89.3 percent at week 20, with high anti-HBs antibodies. Interim safety data showed HEPLISAV-B is well tolerated and no safety concerns were observed. Half of the participants had anti-HBs concentrations ? 1000 mIU/mL.
The study had 119 patients enrolled. It is expected that the last patient visit
will be in
Forward-Looking Statements
This Current Report on Form 8-K contains "forward-looking statements," including
statements regarding expected results for an ongoing clinical trial.
Forward-looking statements can generally be identified by the use of words such
as "anticipate," "believe," "continue," "could," "estimate," "expect,"
"forecast," "intend," "may," "plan," "project," "potential," "seek," "should,"
"think," "will," "would" and similar expressions, or they may use future dates.
Forward-looking statements in this document include, without limitation,
statements regarding the Company's expectations as to the timing of patient
visits and availability of safety data. These forward-looking statements are
subject to assumptions, risks and uncertainties that may change at any time, and
readers are therefore cautioned that actual results could differ materially from
those expressed in any forward-looking statements. Factors that could cause
actual results to differ include, among other things: risks and uncertainties
associated with completion of the study and timing thereof; and other risks and
uncertainties discussed in the Company's filings with the
--------------------------------------------------------------------------------
© Edgar Online, source
